<DOC>
	<DOCNO>NCT02101021</DOCNO>
	<brief_summary>There two phase study . The lead-in phase evaluate safety , pharmacokinetics , define maximum tolerate dose ( MTD ) momelotinib combine nab-paclitaxel gemcitabine adult previously untreated metastatic pancreatic ductal adenocarcinoma . The randomized treatment phase evaluate efficacy , safety , tolerability nab-paclitaxel gemcitabine combine either momelotinib administer MTD placebo adult previously untreated metastatic pancreatic ductal adenocarcinoma measure improvement overall survival ( OS ) , progression free survival ( PFS ) , overall response rate ( ORR ) . Participants continue study treatment disease progression , unacceptable toxicity , consent withdrawal , participant 's refusal treatment . Following treatment , participant follow safety 30 day survival approximately every 3 month 3 year .</brief_summary>
	<brief_title>Gemcitabine Nab-paclitaxel Combined With Momelotinib Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Key Presence metastatic pancreatic adenocarcinoma plus 1 following : Histological diagnosis pancreatic adenocarcinoma confirm pathologically , OR Pathologist confirm histological/cytological diagnosis adenocarcinoma consistent pancreas origin conjunction either : The presence mass pancreas , OR A history resect pancreatic adenocarcinoma Measurable disease per RECIST v1.1 Adequate organ function define follow : Total bilirubin ≤ 1.25 x upper limit normal range ( ULN ) ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 x ULN Absolute neutrophil count ( ANC ) &gt; 1500 cells/mm^3 , platelet &gt; 100,000 cells/mm^3 , hemoglobin &gt; 9 g/dL Serum creatinine &lt; ULN OR calculate creatinine clearance ( CrCl ) ≥ 60 ml/min Eastern Cooperative Oncology Group ( ECOG ) 0 1 Modified Glasgow prognostic score ( mGPS ) 1 2 Screening ( randomized phase ) Key Neoadjuvant adjuvant chemotherapy chemoradiotherapy pancreatic adenocarcinoma Currently previously treat biologic , small molecule , immunotherapy , chemotherapy , agent metastatic pancreatic carcinoma Major surgery within 28 day first dose study drug Minor surgical procedure ( ) within 7 day enrollment yet recover prior minor surgery ( placement central venous access device , fine needle aspiration , endoscopic biliary stent ≥ 1 day enrollment acceptable ) Known positive status HIV Chronic active acute viral hepatitis A , B , C infection ( test require hepatitis B C ) , hepatitis B C carrier Peripheral neuropathy ≥ Grade 2 Known suspect brain central nervous system metastases Diagnosis pancreatic islet neoplasm , acinar cell carcinoma , nonadenocarcinoma , adenocarcinoma originate biliary tree cystadenocarcinoma History interstitial pneumonitis and/or require supplemental oxygen therapy External biliary drain Documented myocardial infarction unstable/uncontrolled cardiac disease within 6 month enrollment Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>